|
Novelos Therapeutics
|
|
Novelos Therapeutics This is a Company that has worldwide rights exclusive of the Russian Federation for two novel Glutathione Pathway Compounds. * NOV-002 this is an adjunct medication delivered IV and subcutaneously along with standard Platinum based Chemotherapy that has been shown in FDA phase II studies to increase cancer patients one year survival rate to almost 65%. * Currently being tested in the US under FDA Phase III SPA FDA_Special_Protocol_Assessment and FDA Fast Track for Approval to be sold in the United States. * Approved for use in Russia and administered to over 10,000 patients. * NOV-205 this is an IV antiviral compound that is marketed in Russia for the treatment of Hepatitis. This medication has completed FDA Phase I trials in the United States. |
| < Prev | Next > |
|---|
Main Menu
| Home |
| Articles |
| Search |
| Submit Article |
| Contact Us |
| Donate to Wikibin |
